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Abstract: Venomous animals use their venoms as tools for defense or predation. These 
venoms are complex mixtures, mainly enriched of proteic toxins or peptides with several, 
and different, biological activities. In general, spider venom is rich in biologically active 
molecules that are useful in experimental protocols for pharmacology, biochemistry, cell 
biology and immunology, as well as putative tools for biotechnology and industries. Spider 
venoms have recently garnered much attention from several research groups worldwide. 
Brown  spider  (Loxosceles  genus)  venom  is  enriched  in  low  molecular  mass  proteins  
(5–40 kDa). Although their venom is produced in minute volumes (a few microliters), and 
contain only  tens of micrograms  of protein,  the use of techniques based on molecular 
biology and proteomic analysis has afforded rational projects in the area and permitted the 
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discovery  and  identification  of  a  great  number  of  novel  toxins.  The  brown  spider 
phospholipase-D family is undoubtedly the most investigated and characterized, although 
other important toxins, such as low molecular mass insecticidal peptides, metalloproteases 
and  hyaluronidases  have  also  been  identified  and  featured  in  literature.  The  molecular 
pathways of the action of these toxins have been reported and brought new insights in the 
field of biotechnology. Herein, we shall see how recent reports describing discoveries in 
the  area  of  brown  spider  venom  have  expanded  biotechnological  uses  of  molecules 
identified in these venoms, with special emphasis on the construction of a cDNA library for 
venom  glands,  transcriptome  analysis,  proteomic  projects,  recombinant  expression  of 
different proteic toxins, and finally structural descriptions based on crystallography of toxins. 
Keywords:  Loxosceles;  brown  spider;  venom;  recombinant  toxins;  biotechnological 
applications 
 
1. The Spiders of Genus Loxosceles and Loxoscelism 
The spiders of the Loxosceles genus, commonly denoted as brown spiders, belong to the family 
Sicariidae, sub-order Labidognatha, order Araneida, class Arachnida, and phylo Arthropoda [1,2]. 
The Sicariidae family also comprises the spiders of Sicarius genus. Strong evidences show that the 
genera  Loxosceles  and  Sicarius  are  old,  having  originated  from  a  common  sicariid  ancestor  and 
diversified  on  Western  Gondwana,  before  the  separation  of  the  African  and  South  American 
continents. Both sicariid genera are diverse in Africa and South/Central America. Loxosceles spiders 
are  also  distributed  in  North  America  and  the  West  Indies,  and  have  species  described  from 
Mediterranean Europe and China. Apparently African and South American Sicarius have a common 
ancestor and South African Loxosceles are derived from this group. New World Loxosceles also have a 
common ancestor and fossil data is consistent with the hypothesis of North America colonization by 
South American Loxosceles via a land bridge predating the modern Isthmus of Panama [3].  
The color of spiders of this genus ranges  from a fawn to dark brown  (Figure 1A). Loxosceles 
spiders have a violin-shaped pattern on the dorsal surface of their cephalothorax, vary in length from 
1 cm to 5 cm, including legs, and have six eyes arranged in non-touching pairs in a U-shaped pattern 
(Figure 1B). This positioning of eyes has been described as the best means of identifying these brown 
spiders [4–8]. The brown spiders are sedentary, non-aggressive, have nocturnal habits and prefer to 
inhabit dark areas. In human habitats, brown spiders are often found behind furniture, pictures and 
associated with clothes. 
Accidents involving Loxosceles genus spiders occur mainly in the warmest months of the year, 
predominantly during spring and summer [4,6]. The condition caused by brown spiders, categorized as 
Loxoscelism,  is  associated  with  a  series  of  clinical  symptoms  including  cutaneous  lesions,  which 
spread gravitationally from the spider bite. The lesions are characterized by necrotizing wounds that 
are dark blue-violet in color and become indurated, leading to the formation of scar tissue. Surrounding 
the lesion, there is also erythema and edema. At the systemic level (less frequent than the appearance 
of skin lesions), patients may experience fever, weakness, vomiting, pruritic reactions, renal failure, Toxins 2011, 3                                 
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and  hematologic  disturbances  that  may  include  thrombocytopenia,  disseminated  intravascular 
coagulation and hemolytic anemia [5,6,8,9]. 
Figure 1. Brown spider aspects. (A) Loxosceles intermedia adult specimens—female and 
male.  (B)  Violin-shaped  pattern  (arrow)  on  the  dorsal  surface  of  cephalothorax  from 
Loxosceles  intermedia  adult  spider,  and  its  six eyes  arranged  in  pairs  as  a  semi-circle 
(arrowheads). (C) Venom harvesting by electric shock applied to the cephalothorax. Arrow 
points for a drop of Loxosceles intermedia venom. Briefly, venom is extracted using an 
electric shock of 15 V applied to the cephalothorax of the spider and the venom from the 
tips of the fang is collected and diluted in phosphate buffered saline (PBS) or dried and 
stored  at  -80º   C  until  use.  (D)  Brown  spider  venom  glands  of  Loxosceles  intermedia 
observed by stereo dissecting microscope (40X). Venom can be harvested directly from 
venom glands: the removed glands are washed in PBS and the venom is obtained by gentle 
compression of the glands. 
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2. The Loxosceles Venoms 
Over recent years, Loxosceles genus spider venoms have been studied by several scientific research 
groups worldwide, and many different toxins have been identified in the venoms. The corresponding 
biological and biochemical properties of these toxins have been reported, yielding insights into the 
pathophysiology of envenomation [4,5,7]. The venom of Loxosceles spiders is a complex mixture of 
protein and peptide toxins with a molecular mass profile ranging from 1 to 40 kDa [5]. To date, several 
molecules in the Loxosceles spider crude venoms have been described, including alkaline phosphatase 
[5,10], 5‘-ribonucleotide phosphohydrolase [5], sulfated nucleosides [11], hyaluronidase [5,12–14], 
fosfolipases-D [5,15–17], metalloproteases, serine proteases [12,13,18–22] and insecticide toxins [23]. 
Table 1 contains a brief collection of main features from proteic toxins described in Loxosceles genus.  
Low molecular weight components, such as neurotoxic and non-neurotoxic peptides, polyamines 
and other components are poorly studied in Loxosceles venom. Using NMR-spectroscopy, Schroeder 
and colleagues (2008) showed that sulfated guanosine derivatives comprise the major small-mollecule 
components of the brown recluse spider. They detected cross-peaks corresponding to 2,5-disulfated 
guanosine  and  2-sulfated  guanosine.  It  appears  that  sulfated  nucleosides  occur  in  several  spider 
superfamilies, such as Agelenoidea and Amaurobioidea. The physiological properties of the sulfated 
nucleosides remain largely unexplored [11]. 
Serine proteases were already described in Loxosceles venom as high molecular weight enzymes 
(85–95 kDa) with gelatinolytic activity activated by trypsin [19]. Proteome and transcriptome analyses 
of Loxosceles venom also described this family of proteases [24,25]. Serine proteases generally are 
among the best characterized venom enzymes affecting the hemostatic system. However, the exact role 
of serine proteases in envenomation still remains to be clarified. 
Recently, by using a cDNA library and transcriptome analysis, a novel expression profile has been 
elaborated for Loxosceles intermedia gland venom. This recently developed profile has allowed the 
identification of additional toxins as components of the venom, including insecticidal peptides similar 
to  knottins  (molecules  that  form  an  inhibitor  cystin  knot),  astacin-like  metalloproteases,  venom 
allergen, a translationally controlled tumor protein family member (TCTP), serine protease inhibitors, 
and neurotoxins similar to Magi 3 [26,27]. Brown spider venoms display a broad diversity of toxin 
isoforms, including members of the phospholipase-D family and astacin-like toxins, even in the same 
sample [17,27–29]. Such features, which represent an adaptation to increase the survival of the spiders 
and the effectiveness of venoms, confer advantages to the spider predator. To confirm the existence of 
a  new  family  of  toxin  isoforms,  it  is  necessary  to  further  characterize  their  biological  properties. 
Recently,  a  spider  toxin  database  called  Arachnoserver  which  was  manually  curated  [30],  has 
cataloged 54 toxins from Sicariidae spiders family. It was elaborated, based on information gleaned 
through  studies  on  complex  venom  mixtures,  and  has  resulted  in  an  exponential  increase  in  the 
identification of peptide-toxins. King et al. [31] recommend a rational nomenclature for naming toxins 
from spiders and other venomous animals to avoid the continued use of ad hoc naming schemes that 
introduce  confusion  and  make  it  difficult  to  compare  toxins  among  species  and  establish  
evolutionary relationships. Toxins 2011, 3                                 
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Table 1. An overview of toxin families in Loxosceles genus. 
Toxins 
MW 
(kDa) 
Characteristics and actions described  No. Seq * 
Phospholipases-D 
(SicTox family 
members, such as 
LiRecDTs)  
30–35 
Several isoforms with variant features such as: 
- Dermonecrosis [12,13,16,32–38] 
- Lipids hydrolysis [33,39–42] 
- Hemolysis [38,43–45] 
- In vitro platelet aggregation [34,36,37] 
- Infiltration of inflammatory cells [35–37,42] 
- Edema [34,38] 
- Renal disturbances [35,46] 
- Lethality [34,38,46,47] 
- In vitro cytotoxicity [35,42,46]  
- Cytokine activation [41,48–50] 
335 
Insecticidal peptides   5–8 
- LiTx family members [23,27] and Magi 3-related 
peptides [23,27,51] 
- LiTx: Lethal to S. frugiperda  
(flaccid paralysis) [23] 
- LiTx3: appears to act upon Na
+ channels [23] 
8 
Metalloproteases  28–35  
- Astacin-like Metalloprotease (LALPs) [29,52] 
- Present in the venom of different species of 
Loxosceles  genus [12,13,27,51,53] 
- Activity upon gelatin, fibronectin, fibrinogen and 
entactin [18,52–54] 
4 
Hyaluronidases   41–43 
- Classified as endo-beta-N-acetyl-d-
hexosaminidases hydrolases [14] 
- Activity upon hyaluronic acid and chondroitin 
sulphate [13,14] 
- Present in the venom of different species of 
Loxosceles  genus[12–14,24,27,51,55] 
- 
Serine-proteases   85–95  
- Gelatinolytic activity [19] 
- Activated in vitro by trypsin [19] 
- Present in the venom of L. intermedia  
and L. laeta [27,51] 
- 
Serine/Cysteine 
protease inhibitors  
N.D. 
- Belongs to Serpin superfamily [27] 
- Identified in Loxosceles spp. transcriptomes and 
proteome [24,27,51] 
- May be related to coagulation processes, 
fibrinolysis and inflammation [51] 
- 
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Table 1. Cont. 
TCTP (translationally 
controlled tumour 
protein) 
~46  
- Identified in Loxosceles spp.  
transcriptomes [27,51] 
- Putative functions: Histamine releasing factor in 
extracellular environment; several intracellular 
roles such as embryonic development, cell 
proliferation, stabilization of microtubules [56] 
- 
Lectin-like  N.D. 
- Putative features: carbohydrate-binding 
molecules; involved in extracellular matrix 
organization, endocytosis, complement  
activation, etc. [51] 
- 
Alkaline-phosphatase   N.D. 
- Degrades the synthetic substrate  
p-nitrophenyl phosphate[10] 
- 
ATPase   N.D  - ATP hydrolysis [10]  - 
N.D.: not determined. *Number of sequences deposited in PUBMED protein database. 
3. The Rational Use of Venom Toxins as Biotechnological Tools 
The idea of using venom toxins as tools for biological purposes is currently gaining acceptance 
worldwide, as researchers incorporate the use of novel technologies to overcome old obstacles such as 
low venom volumes. Technological advancement has led to better techniques for protein purification; 
different models for synthesis of recombinant toxins; structural views of molecular domains, binding 
sites or catalytic sites of molecules of interest; design of synthetic inhibitors or agonists; and finally, 
cellular and animal models for testing the products obtained. The use of toxins directly as a source of 
materials  to  produce  medicines  or  similar  products  has  been  receiving  much  attention  from  the 
pharmaceutical  industry  and  experts  in  the  field  of  applied  research.  Examples  of  toxin-derived 
biomedicines derived from venoms of different animals are abundant. Venoms from snakes, perhaps 
the best studied example of biotechnological applications among animal venoms, with biologically 
active toxins  in  the cardiovascular system,  central  nervous system,  membrane lipids  and proteins, 
hemostatic system, and muscular system, have led to the discovering of several products used in the 
treatment  of  various  diseases.  These  drugs  include  Captopril  (blood  pressure),  Integrilin  (acute 
coronary syndrome), Aggrastat (myocardial infarct and ischemia), Ancrod (stroke), Defibrase (acute 
cerebral infarction and angina pectoris), Hemocoagulase (hemorrhage), and Exanta (anti-coagulant). 
Toxin-derived  products  from  snake  venoms  have  also  been  used  for  diagnosis.  This  group  of 
compounds  includes  Protac  (protein  C  activator,  diagnosis  of  hemostatic  disorders),  Reptilase 
(diagnosis of blood coagulation disorder) and Ecarin (diagnostic of hemostatic disorder) (for review, 
see [57,58]).  
Other toxin-derived medicines have been prepared from components of marine cone snail venoms, 
called conotoxins, which are potent ion channel modulators, and have facilitated the discovery of a 
novel analgesic agent named ziconide, used in the treatment of pain syndromes [59,60]. The honeybee 
venom toxin, called tertiapin (TPN), is an inhibitor of potassium channels, has generated TPNLQ, a 
variant  and  a  potential  novel  model  for  the  treatment  of  hypertension  [61].  Exenatide  (synthetic 
exendin-4) is a toxin-derived medicine from the venom of Gila monster lizard that stimulates the Toxins 2011, 3                                 
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production of insulin by pancreatic cells and has the potential to treat type 2 diabetes [62,63]. Scorpion 
venom toxins have been studied as well, and a large number of molecules with biological activities as 
pain-killers,  agents  that  control  the  spread  of  cancer,  and  natural  insecticides  can  be  generated. 
Scorpion venom, such as kurtoxin and anuroctoxin, can target specific mammalian cell ion channels 
and  their  isolation  has  opened  possibilities  for  drug  design  in  the  context  of  neurologic  and 
autoimmune diseases [64,65]. Other scorpion venom toxins (beta-toxins) can selectively interact with 
insect voltage-gated sodium channels and can be used as toxin-based pesticides [66]. Sea anemone 
venom toxins have been reported as potential agents for the treatment of autoimmune diseases such as 
multiple sclerosis, rheumatoid arthritis and type I diabetes [67]. These toxins, such as Shk, a 35-residue 
polypeptide  toxin  that  is  a  potassium  channel  blocker,  have  proven  to  be  very  useful  sources  of 
pharmacological tools. Furthemore, the molecule‘s analogs have been evaluated with regard to the 
development of new biopharmaceuticals for autoimmune disorders [68,69].  
With regard to spider venoms, researchers are involved in the study of insecticidal toxins, which can 
be used as tools in the elaboration of environmentally safe pesticides. Notably, the venom of the 
Australian  funnel  web  spider  has  been  analyzed,  with  emphasis  on  the  toxin  omega-atracotoxin 
(ALTX) HV1, a 37-residue peptide molecule. One model proposes the use of baculoviruses to express 
spider toxin to act as a pesticide [59,70]. Additionally, spider venom toxins can be used as models for 
the development of transgenic plants expressing insecticidal toxins. One example of this situation is 
the case of omega-ACTH-Hvt1 toxin from  the venom  of  Hadronyche  versuta, which protects  the 
tobacco plant against insects. Another rational use of spider venom toxin as a model for design of 
therapeutic agents  involves  use of the toxin from  Phoneutria nigriventer venom  as  a  tool for the 
treatment of erectile dysfunction. The toxin Tx2–6 causes an improvement in the level of nitric oxide 
in penile tissue in rats [71,72]. Additionally, antibacterial peptides were identified in the venom of the 
Cupiennius salei spider. These peptides appear to act as channel-forming toxins within the bacteria 
wall. Analogous synthetic molecules would be expected to have great potential, especially in the age of 
multiple-antibiotic-resistant bacteria and related threats to human health [59,73].  
The  biotechnological  uses  of  Loxosceles  spider  venoms  have  received  increased  attention  over 
recent years. Notably, a spider toxin-derived product (ARACHnase) was proposed for the diagnosis of 
lupus anticoagulant. Also, antisera produced with Loxosceles venom has been used as bioproducts for 
serum therapy after spider accidents (for more information, see [74]). Recently, several recombinant 
toxins from L. intermedia, L. laeta, L. boneti, L .gaucho, and L. reclusa have been described. These 
include members of the phospholipase-D family [32–37,39,43], members of metalloprotease/astacin 
family [29,52], a member of translationally controlled tumor protein family (TCTP), a hyaluronidase, a 
serine protease inhibitor, a venom allergen, an insecticide toxin, member of neurotoxin/Magi 3 family , 
and an insecticidal toxin [75]. Recombinant molecules will not only expand our knowledge of spider 
biology and the pathophysiology of Loxoscelism, but as we shall discuss in the next chapters, they will 
also provide additional molecules for biotechnological purposes [74]. 
4. Phospholipase-D 
Phospholipase-D  is  the  most  studied  type  of  molecule  present  in  the  venom  from  Loxosceles 
species. In the general literature, these toxins are referred to as sphingomyelinase-D, due to their first Toxins 2011, 3                                 
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biochemical  description  as  enzymes  capable  to  hydrolyze  sphingomyelin  substrate.  Based  on  the 
IUBMB  recommendations,  these  molecules  are  biochemically  classified  as  sphingomyelin 
phosphodiesterases D (E.C. 3.1.4.41) [5,6] Dermonecrotic toxin is a biological term widely applied by 
toxinologists to Loxosceles phospholipase-D, due to the hallmark of brown spider bites, which trigger 
dermonecrosis in vivo. Kalapothakis et al. [17] have organized dermonecrotic toxins of L. intermedia 
into  a  protein  family,  denoted  LoxTox,  by  using  cDNA  coding  sequences  of  several 
dermonecrotic/sphingomyelinase proteins from Loxosceles intermedia. The authors present at least six 
distinct groups (LoxTox 1 to 6) based on similarities among the molecules. At the present moment, 
Arachnoserver [30] includes 49 toxins from the Loxosceles genus with biological activity patterns 
characterized by dermonecrosis; these toxins were denoted as brown spider phospholipase-D proteins 
or partial sequences following the phylogenetic analyses of sicariid SMases by Bindford et al. [1].  
The Loxosceles and Sicarius genera uniquely share the dermonecrotic venom toxin phospholipase D 
within  the  Haplogyne  lineage.  The  most  prospective  evolutionary  scenario  for  the  origin  of  this 
enzyme is a single origin in the most recent ancestor of the Sicariidae family [76]. Phospholipases-D 
vary  in  molecular  mass  between  species  of  North  American  Loxosceles  (31–32  kDa),  Old  World 
species  (32–33.5  kDa)  and  South  American  Loxosceles  (32–35  kDa)  [76].  Sphingomyelinase-D 
activity  can  be  detected  in  all  (36)  Loxosceles  and  Sicarius  species  already  tested.  Binford  and 
colleagues (2008) proposed to call this specific gene family SicTox towards a rational nomenclature. 
Based on Bayesian analyses they also resolved two clades of SMD genes, labeled ʱ and β. Sequences 
in the ʱ clade are exclusively from New World  Loxosceles and Loxosceles rufescens and include 
published genes for which expression products have SMase D and dermonecrotic activity. The β clade 
includes  paralogs  from  New  World  Loxosceles  that  have  no,  or  reduced,  SMase  D  and  no 
dermonecrotic  activity  and  also  paralogs  from  Sicarius.  In  the  context  of  structural  position  and 
proposed active sites [40], ʱ and β clades differ only in conservation of key residues surrounding the 
apparent substrate binding pocket [3].  
The  pathological  mechanisms  of  brown  spider  phospholipase-D  have  been  continuously 
investigated,  Van  Meeteran  [48]  and  Lee  and  Lynch  [41]  observed  that  recombinant  Loxosceles 
SMaseD isoforms are able to hydrolyze lysophospholipids, generating bioactive lipid mediators such 
as lysophosphatidic acid (LPA). These researches extended the boundary of knowledge, which had 
depended upon sphingomyelin as a well-known substrate molecule. Furthermore, Lee and Lynch [41] 
also postulate that the term phospholipase-D (PLD) would more effectively represent the broad range 
of hydrolysable phospholipids than previously supposed to be applied for dermonecrotic toxins from 
Loxosceles  genus  [48]. Nomenclature of these toxins should be updated to  account  for the recent 
accumulation of knowledge regarding the biological and biochemical properties of these compounds. 
The great interest of toxinologists in PLD proteins, to the neglect of other toxins present in the 
venom (most of them also enzymes or bioactive peptides), is due to the ability of these proteins to 
reproduce many effects of necrotic arachnidism or Loxoscelism. The PLDs from the Loxosceles genus 
are described as being responsible for several biological properties ascribed to whole venom, including 
the  following:  dermonecrosis,  massive  inflammatory  response  with  neutrophil  infiltration  and 
complement activation, platelet aggregation, immunogenicity, edema and increased blood vessel wall 
permeability,  hemolysis,  renal  failure,  toxicity  for  several  cultured  cell  types,  and  animal  
lethality [4,38,74,77].  Toxins 2011, 3                                 
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Clinical  investigations  by  Futrell  [5]  indicated  that  a  dermonecrotic  factor  was  responsible  for 
histopathological  observations  resembling  those  of  the  cutaneous  Arthus  reaction,  as  observed  in 
victims of accidents with brown spiders. Futrell [5] also reported the native toxin from L. reclusa  
(32 kDa) was an enzyme that hydrolyzes sphingomyelin and releases choline and N-acylsphingosine 
phosphate (or ceramide 1-phosphate). Various isoforms of phospholipase D were already reported for 
different species. Using SDS-PAGE analysis and chromatography methods, a range of molecular mass 
between  30–35  kDa  was  determined  for  PLD  toxins  that  have  hemolytic,  necrotic  and  platelet 
aggregation activity, from  L. reclusa, L. rufescens, L. gaucho, L. laeta and L. intermedia venoms 
[5,15,16,44,47,78,79]. Advances in proteomic studies have facilitated the description of many more 
PLD-related proteins in whole venom. Luciano et al. [80] performed two-dimensional electrophoresis 
and observed enriched levels of a 30-kDa molecule as well as cationic properties in L. intermedia 
whole venom, indicating the presence of several PLD-related protein spots. Furthermore, proteomic 
analysis  of  L.  gaucho  whole  venom  led  to  the  identification  of  at  least  eleven  PLD  proteins  
(30–32  kDa  ‗loxnecrogin‘  isoforms)  by  Edman  chemical  sequencing  and  capillary  liquid 
chromatography-mass spectrometry [25]. In summary, PLDs are dermonecrotic toxins that comprise a 
family of toxins with different related isoforms that have biological, amino acid and immunological 
similarities  and  which  are  found  in  diverse  Loxosceles  species  [4,27,38,74].  This  variation  in 
phospholipase-D  molecules  may  be  due  to  post-translational  modification  and  the  expression  of 
paralogous  genes, since recent data demonstrate that gene duplications are frequent and that  PLD 
genes lie in a region with high recombination within the genome [3]. 
Nowadays, heterologous systems based on cDNA sequences encoding mRNA transcripts from the 
brown  spiders  are  a  very  useful  tool  for  the  production  of  recombinant  PLD  proteins  (mainly  in 
prokaryotic models). Using extracts of the venom gland, which is the tissue that is specialized for the 
production and secretion of venom toxins, molecular biology techniques were optimized to obtain 
several sequences as template for the identification, characterization and recombinant expression of 
PLD proteins [74].  
At present, a new generation of molecules developed through cloning techniques still remains under 
investigation  by  researchers  aiming  to  determine  molecular  and  cell  mechanisms  of  PLDs  by 
biological approaches. L. intermedia LiD1 recombinant protein (31.4 kDa) is a sphingomyelinase D 
family molecule without dermonecrotic activity but with antigenic activity [32]. L. laeta recombinant 
protein  (33  kDa)  is  a  sphingomyelinase  isoform  able  to  degrade  sphingomyelin  [43].  L.  laeta 
recombinant phospholipase-D generates lysophosphatidic acid and induces lysis of red blood cells 
[41]. Keratinocyte apoptosis was induced by recombinant PLD (SMaseD P2) from L. intermedia [81]. 
Global  gene  expression  changes  in  fibroblast  cells  induced  by  PLD  recombinant  protein  from  
L. recluse (SMD) are related to components of inflammatory response, such as human cytokines, genes 
involved in the glycosphingolipid metabolism pathway, and proteins known to impact transcriptional 
regulation [49]. Six isoforms of phospholipase-D were cloned from a cDNA library of L. intermedia 
gland venom and then expressed; they were shown to have similar toxic effects to those of native 
venom toxins [34–38]. L. intermedia recombinant protein (LiRecDT1, 34 kDa) displays dermonecrotic 
activity and was able to directly induce nephrotoxicity in mice and cultured tubular epithelial cells 
[42,46]. It could also induce non-complement-dependent hemolysis in vitro and inflammatory response 
using endothelial cell membrane as target [42,45]. Nephrotoxicity and hemolysis are both toxic effects Toxins 2011, 3                                 
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that  depend  directly  on  catalytic  enzyme  activity.  In  the  same  way,  LiRecDT2  (ABB69098), 
LiRecDT3  (ABB71184),  LiRecDT4  (ABD91846),  LiRecDT5  (ABD91847),  and  LiRecDT6 
(ABO87656) were identified, cloned and characterized as PLD proteins with high similarity to each 
other based on sequence alignment; this similarity is due primarily to conserved amino acids at the 
catalytic site [34–37]. The results of this alignment corroborated with the crystal structure analysis of a 
dermonecrotic toxin [40] from L. laeta, which suggested there were conserved residues at the proposed 
catalytic site for SMase D. The recent transcriptome analysis of L. intermedia venom gland identified 
at least two clusters (annotated as PLD-related ESTs) as new possibilities for a novel PLD isoform in 
L. intermedia venom, adding a new group to the LoxTox family classification [17,27].  
The  knowledge  of  structural,  biochemical  and  biological  properties  of  PLD  toxins  could  be 
employed in design studies for the development of new drugs, biopharmaceuticals, diagnostic tests and 
other biotechnological and industrial applications. Immunoassays using brown spider PLDs as probes 
have  been  tested  [50,82]  because  differential  diagnosis  of  brown  spider  bites  can  often  lead  to 
misdiagnosis [83,84]. Moreover, therapeutic serum development and vaccination have been studied to 
ascertain the benefits of antivenom [85,86]. Synthetic peptides designed based on PLDs toxins with 
specific biological/protective effects have also been utilized [87,88]. Additionally, brown spider PLDs 
could be employed in the development of a vaccine derived from the phospholipase-D-mutated toxin 
from L. intermedia (substitution of the Histidine12 for Alanine in the catalytic site—LiRecDT1H12A) 
for the immunization of people living in regions that are endemic for accidents involving Loxosceles 
spiders.  This  method  may  be  useful  because  enzyme  activity  of  LiRecDT1H12A  is  dramatically 
decreased and has neither hemolytic activity nor nephrotoxicity [45,46]. Another possible application 
for  PLD  is  as  reagent  of  immunodiagnostic  assays  for  identification  and  quantification  of 
phospholipase-D in the sera of patients bitten by Loxosceles spider because diagnosis of Loxoscelism 
is  very  controversial  and  is  commonly  based  on  clinical  signs  and  symptoms  [89].  Brown  spider 
venom  may  be  detected  in  hair,  wound  aspirates,  and  skin  biopsy  for  at  least  seven  days  after 
inoculation [90].  
PLD  enzyme  activity  triggers  the  degradation  of  the  cell  membrane  phospholipids,  loss  of 
membrane  asymmetry,  phosphatidylserine  exposure  and  membrane  reorganization  [91–93]. 
Sphingomyelin  degradation  changes  membrane  properties,  such  as  lipid  raft  organization  and 
membrane  fluidity,  triggering  intracellular  pathways  [94,95].  Phospholipid  metabolites  induce  the 
release  of  prostaglandins,  activate  the  complement  cascade,  stimulate  platelet  aggregation,  and 
enhance neutrophil chemotaxis and inflammation. Brown spider PLD toxins could be used in lipid 
protocols for cell membrane studies related to biological effects of lipid metabolites, with emphasis on 
sphingolipid-derived bioactive molecules and their signaling pathways. The activity and expression of 
some phospholipases are increased in several human cancers, suggesting that these enzymes may have 
central roles in tumor development and progression [96,97]. This involvement raises the possibility of 
considering phospholipid metabolism as a potential target for the development of new antitumoral 
agents by using brown spider PLDs as a novel model for tumor cell studies.  
Further  studies  improving  the  understanding  of  PLD  catalysis  are  relevant  not  only  for 
comprehension of phospholipases mechanisms in basic sciences, but also for related pharmaceutical 
and biotechnological applications [98]. The catalytic activity of brown spider PLD plays a role in the 
pathological  activity  of  this  toxin  and  therefore  cannot  be  dismissed  as  a  rational  target  for  new Toxins 2011, 3                                 
 
 
319 
strategies to treat Loxoscelism. Degradation of the phospholipid head-groups by brown spider PLDs 
changes membrane surface potential and affects the functional properties of some cation channels. 
Brown spider PLDs can offer an effective pharmacological way to activate voltage-gated channels that 
could be useful for ―channelopathy‖ studies [99]. Certainly, elucidation of the roles of PLDs in a 
variety of molecular and cell biology mechanisms might be the greatest value of brown spider PLDs as 
a biotechnological product, which depends on their continuous characterization with regard to the 
details of pathogenesis and biochemistry. 
5. Hyaluronidase 
Hyaluronidases  are  enzymes  that  mainly  degrade  hialuronic  acid  (HA),  and  which  may  have 
activity upon chondroitin, chondroitin sulfate (CS) and, to a limited extent, dermatan sulfate (DS) 
[14,100,101]. The hyaluronidases are a group of enzymes that are distributed widely throughout the 
animal kingdom. They were discovered through the observation that extracts of some tissues contained 
a ―spreading factor‖, which facilitated the diffusion of dyes and subcutaneous antiviral vaccines [102]. 
These enzymes are present in the venoms of multiple organisms, such as lizards, scorpions, spiders, 
bees, wasps, snakes and stingrays [103–105].  
Hyaluronidases in venoms have been described as ―spreading factors‖ due to their ability to degrade 
extracellular matrix components and to increase the diffusion of other toxins in tissues adjacent to the 
inoculation site [103]. Data from crystallography and X-ray diffraction suggested the evolutionary 
conservation  of  many  poison  hyaluronidases  in  a  comparative  study  of  several  animal  venoms 
[106,107]. Tan and Ponnudurai [108] reported that all venoms exhibit a wide range of hyaluronidase 
and  protease  activities.  With  regard  to  spider  venoms,  Kaiser  [109]  was  the  first  to  report 
hyaluronidase activity, from Brazilian Lycosa raptoral spiders, now known as Phoneutria nigriventer 
[110]. Shortly after that report, hyaluronidase activity was detected in the venom of European window 
spider L. tredecimguttatus and of the tarantula D. hentzi venom. This enzyme was isolated from the 
funnel web A. robustus and the tarantula E. californicum venom [111]. Spider venom hyaluronidases 
have  been  described  more  recently  in  Lycosa  godeffroy,  Lympona  cylindrata/murina  [110]  and 
Cupiennius  salei[112].  The  Hipassa  genus  showed  similar  hyaluronidase  activity  to  that  of  
H. agelenoides, H. lycosina and H. partita species [110,113]. Moreover, venom obtained from Vitalius 
dubius, a spider found in southeastern Brazil, showed high levels of hyaluronidase activity [114]. With 
regard to necrotizing Australian spiders, hyaluronidase activity was demonstrated in Badumna insignis, 
Loxosceles rufescens, and Lampona cylindrata [12].  
In 1973, Wright  et  al.  were the first  to  describe hyaluronidase activity in  venom  of the genus 
Loxosceles [55]. This work was performed with L. recluse venom, and the purified enzymes, which 
were estimated to have molecular weights of 33 and 63 kDa by SDS-PAGE [115], exhibited activity 
against HA and CS types A, B, and C. The authors also showed that rabbit anti-venom inhibited the 
spreading effect exhibited by whole venom in vivo and completely inhibited hyaluronidase activity 
in vitro [55]. Young and Pincus [12], analyzing L. recluse venom, described hyaluronidase activity for 
a protein determined to be 32.5 kDa by HA-substrate SDS-PAGE [12,115]. Barbaro et al. [13] studied 
venoms from five Loxosceles species of medical importance in the Americas (L. deserta, L. gaucho, 
L intermedia, L. laeta and L. recluse).  Toxins 2011, 3                                 
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Hyaluronidase  activity  was  detected  in  all  species  of  Loxosceles  spider  venom  tested  by  HA 
zymogram. All venom samples contained an enzyme with molecular weight of approximately 44 kDa, 
which was able to digest HA and which may contribute to the characteristic gravitational spread of the 
dermonecrotic lesion in patients suffering from the effects of these venoms [13,115]. da Silveira et al. 
[14]  reported  that  zymography  showed  L.  intermedia  venom  included  hyaluronidase  molecules  of  
41 and 43 kDa molecular weight. The activity of these enzymes is pH-dependent, with optimal activity 
between 6 and 8, and was able to degrade HA in rabbit skin. Pedrosa et al. [51] studying L. laeta 
transcriptome  found  transcripts  with  similarity  to  Bos  Taurus  'hyaluronidase'  (gb|AAP55713.1): 
4 clones  and  1  cluster  (LLAE0048C),  representing  0.13%  of  the  total  sequence.  In  addition, 
hyaluronidase  represents  only  0.1%  of  all  total  toxin-encoding  transcripts  in  the  venom  gland  of  
L. intermedia [27]. This result may explain the difficulty associated with purification this enzyme from 
Loxosceles venoms. To obtain the recombinant hyaluronidase from L. intermedia venom, through the 
use  of  appropriate  molecular  biology  techniques,  an  isoform  was  cloned  and  showed  to  have  a 
theoretical molecular mass of about 46.1 kDa [75].  
Hyaluronidase-mediated degradation of HA increases  membrane permeability, reduces  viscosity 
and  renders  tissues  highly  permeable  to  injected  fluids.  This  degradation  process  is  involved  in 
bacterial pathogenesis, the spread of toxins and venoms, fertilization, and cancer progression [102]. 
Therefore,  brown  spider  hyaluronidase  could  be  used  therapeutically  in  many  fields,  including 
orthopedics, surgery, ophthalmology, internal medicine, oncology, dermatology and gynecology [74]. 
There are several studies showing that hyaluronidases can be used to promote resorption of excess 
fluids,  to  increase  the  effectiveness  of  local  anesthesia  and  to  diminish  tissue  destruction  by 
subcutaneous and intramuscular injection of fluids [100,102]. For example, hyaluronidase has been 
used  to  reduce  the  extent  of  tissue  damage  following  extravasation  of  parental  nutrition  solution, 
electrolyte  infusions,  antibiotics,  aminophyline,  mannitol  and  chemotherapeutic  agents,  including 
Vinca alkaloids [116].  
Additionally,  recombinant  human  hyaluronidase  (rHuPH20)  has  been  used  in  chronic  pain 
management, to improve systemic absorption and bioavailability of drugs [117–120]. In the context of 
cancer therapy, testicular hyaluronidase (HAase) has been added to drug regimens to improve drug 
penetration. In limited clinical studies, HAase has been used to enhance the efficacy of vinblastin in 
the treatment of malignant melanoma and Kaposi‘s sarcoma, among other cancers [121]. Furthermore, 
when  the  level  of  HA  decreases  under  conditions  in  which  hyaluronidase  activity  increases,  the 
moisture  and  tension  of  the  skin  are  reduced,  and  histamine  is  released  from  mast  cells  [122]. 
Therefore, the identification and characterization of hyaluronidase inhibitors could be relevant to the 
development of contraceptives, as well as anti-tumor, anti-microbial, and anti-venom, anti-wrinkle, 
and anti-aging agents, and allergy and inflammation suppressors [14,122–124]. Therefore, Loxosceles 
recombinant hyaluronidases are associated with numerous potential applications [27,74,125,126]. 
6. Translationally Controlled Tumor Protein (TCTP) 
Loxosceles  intermedia  TCTP  protein  was  identified  during  an  L.  intermedia  venom  gland 
transcriptome study [27], although another spider TCTP had already been described from the venom 
gland of Loxosceles laeta by transcriptome analysis [51]. Proteins of the TCTP superfamily were first Toxins 2011, 3                                 
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identified  in  the  late  eighties  by  research  groups  studying  translationally  regulated  genes.  These 
proteins were named translationally controlled tumor proteins when the discovery of human cDNA 
was  published  [127].  This  name  was  based  on  the  protein‘s  tumoral  origin,  a  human  mammary 
carcinoma, and on the observation that TCTP is regulated at the translational level. The translationally 
controlled tumor protein (TCTP), which was initially named P21, Q23 and P23 by three different 
groups and is also called HRF (histamine-releasing factor), represents a large family of proteins that 
are highly conserved and ubiquitous in eukaryotes [56,128].  
Sequence alignment studies of TCTP sequences revealed that nearly 50% of all amino acid residues 
are preserved. Among species from the same genus, TCTPs are completely conserved [56]. When the 
TCTP sequence found in the L. intermedia venom gland transcriptome was compared with the one 
described in the venom gland of L. laeta, 97% similarity was observed. L. intermedia TCTP also 
presented  important  similarities  with  the  other  arthropod  TCTPs,  such  as  Ixodes  scapularis  and 
Amblyomma  americanum  from  mites  [27].  The  scientific  community‘s  understanding  of  TCTP‘s 
biological  function is  growing. The compound  possesses  a wide range of functions,  and different 
biochemical roles are currently being established [56,129].  
Although TCTP participates in various biological functions, the primary physiological roles of this 
protein are still unknown [130]. TCTP is widely expressed in many tissues and cell types, and its 
protein levels are highly regulated in response to a wide range of extracellular signals and cellular 
conditions [56]. Interactions between TCTP and other cellular proteins have already been reported for 
tubulin  [131],  actin-F  [132],  the  mammalian  Plk  [133],  translation  elongation  factors  eEF1A  and 
eEF1Bbeta [134], Mcl-1 [135,136], TSAP6 [137], Na,K-ATPase [138], Bcl-XL [139] and Chrf [140]. 
Studies have already shown that TCTP is essential for embryonic development and cell proliferation in 
mice and Drosophila [141,142]. Moreover, the protein has calcium-binding activity and is capable of 
stabilizing microtubules, a property that may be related to a possible role of TCTP in cell cycle control, 
as it was also shown that TCTP interacts with a checkpoint protein (Chrf) [56,140].  
Loxosceles  intermedia  transcriptome  analysis  highlighted  TCTP  transcript  as  a  toxin-coding 
messenger due to TCTP extracellular activities already described above [27]. TCTP was described as a 
protein  that  triggers  histamine  release  in  basophil  leukocytes  and  was  therefore  called  ‘histamine 
release  factor‘  (HRF)  [128].  Then,  other  studies  reported  that  TCTP  presents  more  general  
‗cytokine-like‘ activity, as it also induces the production of interleukins from basophils and eosinophils 
[143]. TCTP itself is induced by certain cytokines and acts as a growth factor for B-cells [144]. Studies 
demonstrate that TCTP triggers histamine release in basophile leukocytes by mechanisms that may be 
dependent on or independent of the presence of IgE. It is believed that a specific TCTP receptor may 
participate in the process, leading to mast cell activation [56]. Although TCTP protein was found in 
biological fluid of asthmatic or parasitized patients and in saliva from ticks, TCTP mRNAs do not code 
for a signal sequence and no precursor protein has been described [56,145]. TCTP secretion from cells 
proceeds  via  an  endoplasmic  reticulum/Golgi-independent  or  non-classical  pathway,  probably 
mediated by secreted vesicles called exosomes, which have been suggested as possible pathways for 
non-classical secretion [137,145]. In the case of the Loxosceles venom gland, TCTP is secreted via 
holocrine secretion [27]. TCTPs have been described in gland secretions of many arthropods, such as 
ixodid ticks and in the venom gland of the wolf spider [146–148].  Toxins 2011, 3                                 
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L. intermedia TCTP is very similar to Dermacentor variabilis TCTP, which is expressed in diverse 
tissues from the tick, including its salivary gland. When this TCTP was cloned and expressed as a 
recombinant protein, it was able to release histamine from a basophilic cell line [27,146]. Based on 
these data, it is possible to suggest that L. intermedia TCTP may act as a histamine release factor. The 
presence  of  a  component  in  L.  intermedia  venom  related  to  the  histaminergic  activity  of  venom 
supports  with  this  hypothesis  [149].  Recently,  some  authors  have  called  attention  to  the  role  of 
histamine and its receptors in the development of edema, involving increased vascular permeability 
and vasodilatation [150], which occurs in Loxoscelism. Histamine had been described as the principal 
pharmacological component in the venom of the wolf spider (Lycosa godeffroyi) [148,151]. Proteins of 
the TCTP family were described to be expressed in human parasites suggesting that could be related to 
the survival mechanisms of parasites in the host and to the onset of pathological processes [152–154]. 
The antimalarial drug artemisin [155], probably acts on Plasmodium TCTP, confirming its important 
function in the development of pathology [153,154].  
Recently,  an  increasing  number  of  researchers  have  focused  their  attention  on  the  cellular  and 
extracellular  activities  of  TCTP,  as  it  has  been  implicated  in  the  promotion  of  cell  growth  and 
tumorigenesis  as  well  as  in  protection  against  apoptosis  and  other  consequences  of  cell  stress  
[56,156–158]. TCTP protein levels are upregulated in cancer cells and in human tumors [159–161]. 
Downregulation of TCTP has been implicated in biological models of tumor reversion [159,162], and 
the protein is the target of various anticancer drugs [159,163]. TCTP has been proposed as a potential 
cancer biomarker [160,164,165] and therapeutic target [166].  
TCTP  has  enormous  biotechnological  potential;  this  toxin  presents  a  wide  range  of  putative 
applications: from a biological tool at research laboratories to clinical oncology, as a biomarker and/or 
a model for drug design to cancer treatment. Drugs that cause inhibition of TCTP activity resulted in 
tumor growth inhibition both in vitro and in vivo [159]. TCTP and its biological tools (e.g., antibodies 
against  TCTP)  can  also  be  used  in  experimental  oncology  to  study  tumor  cell  behavior  and 
metabolism, as well as in the screening of anticancer drugs. Still in the field of cell proliferation, TCTP 
and its related biological tools could also be used to study cell cycle regulation and the microtubule 
cytoskeleton, as well as its role in cell physiology and organelle transport.  
Calcium metabolism and signaling are other issues that could be explored using TCTP and its 
derived biological tools. Antiapoptotic activities were also described for TCTP: this protein potentiates 
MCL1 and BCL-XL inhibits BAX [158]. These effects highlight TCTP as a candidate for apoptosis 
studies, as an apoptotic drug and as a model for anti-apoptotic reagents. Another possible application 
of this toxin could be its employment in allergic screening tests, due to TCTP‘s histaminergic activity. 
Inhibitors of TCTP are putative anti-histaminic drugs and other TCTP-derived biological tools could 
be useful at research laboratories that study histamine release, mast cell metabolism and activation, 
immediate  hypersensitivity  reactions  and  the  allergy  process  in  general.  Protocols  that  involve 
proliferation  of  B  cells  represent  other  potential  applications  for  TCTP.  TCTP  secretion  to  the 
extracellular milieu is mediated by a non-classical pathway involving exosomes [137]; therefore, it is a 
good reagent with which to study this type of cellular secretion. TCTP has a surprising number of 
different functions as described here, but how these different functions might be interrelated remains to 
be determined [167]. Therefore the putative applications suggested herein are just the first insights into 
the potential uses and applications of TCTP in the field of biotechnology. Toxins 2011, 3                                 
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7. Astacin-Like Metalloproteases 
Metalloproteases in Loxosceles venom were first characterized in L. intermedia venom. Feitosa et al. 
[18]  described  two  metalloproteases,  Loxolisin  A  (20–28  kDa,  with  fibronectinolytic  and 
fibrinogenolytic activity) and Loxolisin B (32–35 kDa, with gelatinolytic activity). Zanetti et al. [168] 
purified  a  30  kDa  molecule  with  fibrinogenolytic  activity  from  L.  intermedia  crude  venom. 
Furthermore, da Silveira et al. [53] showed that venom gland extracts from brown spiders possess 
proteolytic activity, and this activity could be inhibited by bivalent chelators. This study proved that 
metalloproteases are components of L. intermedia and L. laeta venoms, and eliminated the possibility 
that electrostimulated venom could have been contaminated with digestive hydrolytic enzymes during 
extraction [53].  
Metalloproteases were also identified as components of different Loxosceles species venoms, such 
as L. rufescens, L. gaucho, L. laeta, L. deserta and L. reclusa [12,13,51,168]. Recently, a recombinant 
metalloprotease  from  the  L.  intermedia  venom  gland,  named  LALP  (Loxosceles  astacin-like 
metalloprotease),  was  characterized  as  an  astacin-like  enzyme.  This  functional  characterization 
supported previous data describing metalloproteases in Loxosceles venom [52]. The identification of 
LALP in L. intermedia venom was the first report in the literature of the presence of an astacin family 
member as an animal venom constituent. Trevisan-Silva et al. [29] described two new astacin-like 
toxin isoforms from L. intermedia venom (LALP2 and LALP3) and found that metalloproteases in  
L. laeta and L. gaucho  venoms are also members of the astacin family. This study described the 
presence of  a  gene family of  astacin-like toxins  in  three  Loxosceles  species  suggesting that these 
molecules will be found in all South America Loxosceles species [29]. Astacin-like proteases are the 
second most commonly expressed class of toxins in the L. intermedia venom gland, comprising 9% of 
all transcripts [27].  
The astacin family enzymes are zinc-dependent metalloproteases, which are considered as part of 
the metzincin superfamily [54,169]. Members from the astacin family are ubiquitous, existing more 
than 200 described astacins, which are found in some bacteria species and in all animal kingdoms 
[169–173].  Astacins  are  characterized  by  the  zinc-binding  motif  (HEXXHXXGXXHEXXRXDR), 
which contains three histidine residues that are responsible for the complexation of zinc. Below the 
active site, all astacins have a methionine residue within a typical Met-turn (SXMXY), with a tyrosine 
residue that might be involved in substrate fixation [54,169,174–176]. This protease family was named 
after the identification of astacin from freshwater crayfish, Astacus astacus. Astacin is the prototypical 
digestive collagenolytic enzyme of the astacin family [177,178]. Astacin family members are reported 
to  have  a  wide  range  of  functions,  playing  roles  in  digestion,  in  peptide  and  matrix  molecules 
processing,  in  the  activation  of  growth  factors  and  in  the  degradation  of  distinct  
proteins [169,174,175].  
We have little information about the biochemical and biological  function of  Loxosceles venom 
astacins because astacin members have distinct functions and the study of astacins from Loxosceles 
venoms  is  just  beginning.  Previous  studies  of  Loxosceles  metalloproteases  have  shown  that  they 
degrade  some  matrix  proteins  (fibronectin,  fibrinogen,  gelatin  and  entactin),  but  the  mechanism 
involved in the noxious effect of the venom is until unclear [18,20,21,52]. It has been suggested that 
astacin  toxins  could  be  involved  in  gravitational  spreading  of  dermonecrosis,  in  hemorrhagic Toxins 2011, 3                                 
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disturbances observed in accidents, imperfect platelet adhesion and increased vascular permeability, 
which can occur near bite sites after brown spider accidents [13,29,52]. Also, astacin proteases could 
act as a spreading factor for other venom toxins and could serve as important agents, in the processing 
of  other  venom  toxins,  by  cleaving  inactive  proteins  and  generating  active  peptides  that  may  be 
involved in Loxoscelism effects [29,52].  
Astacin-like  proteases  are  biologically  active  enzymes  that  have  potential  applications  in 
pharmaceutical studies and could be used as tools for research protocols [74]. The enzymatic activities 
of astacins upon different proteins highlight these molecules as useful tools in studies involving protein 
degradation, especially the degradation of extracellular matrix (ECM) components. Considering the 
physiological and pathological events related with ECM degradation, astacins can be used in protocols 
for medical and pharmaceutical research, such as ECM assembly and remodeling (including collagen 
processing  and  the  healing  process).  Drug  administration  (as  a  co-adjuvant),  cell  membrane 
metabolism,  embryogenesis,  cellular  differentiation  (including  stem  cells),  tumorigenesis  and 
metastasis,  enzymatic  activation  (latency  and  activation  of  zymogens),  cell  signaling  based  on 
proteolysis,  inflammatory  response  and  vascular  permeability  are  other  potential  applications  for  
these molecules.  
Astacins from L. intermedia could also be used as starting materials to design new drugs/molecules, 
as agonists and/or inhibitors. One possible therapeutic use of astacins from L. intermedia is the context 
of vascular diseases (acute myocardial infarction, acute ischemic stroke, thrombosed aortic aneurysms, 
pulmonary embolism, etc.) and as thrombolytic agents. At present, intravenously administered tissue 
plasminogen activator (IV-TPA) remains the only FDA-approved therapeutic agent for the treatment 
of  ischemic  stroke  within  three  hours  of  symptom  onset.  Although  intra-arterial  delivery  of  the 
thrombolytic agent seems effective, various logistic constraints limit its routine use and, as yet, no lytic 
agent has received full regulatory approval for intra-arterial therapy [179]. Moreover, astacin inhibitors 
may be therapeutically useful in atherosclerosis prevention. Meprins, which are members of the astacin 
family, hydrolyze and inactivate several endogenous vasoactive peptides, some of which could alter 
various  functions  of  cells  in  the  arterial  wall.  Recent  studies  have  shown  that  a  meprin  inhibitor 
suppresses the formation of atherosclerotic plaques [180]. The recombinant astacins could also be used 
as reagents for laboratorial tests to diagnose Loxoscelism, as well as anti-loxosceles serum production, 
in the treatment of envenomation. 
8. Insecticidal Peptides 
Spider venoms are functionally related to defense against predators and primarily used to paralyze 
and  capture  natural  prey,  especially  insects  [89,181–183].  To  execute  these  functions,  spiders 
developed an arsenal of insecticidal molecules in their venoms, resulting in a combinatorial peptide 
library  of  insecticidal  peptides  that  has  been  improved  over  the  course  of  evolution  [184].  Such 
peptides consist of single-chain, low molecular weight molecules of 3–10 kDa, with a high number of 
cysteine residues that form intramolecular disulfide bridges  [185,186]. Over the last decade, these 
peptides have been investigated extensively through identification, purification, characterization and 
cloning studies [23].  Toxins 2011, 3                                 
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The insecticidal peptides act in the nervous system of prey or predator, causing paralysis or even 
death, by interacting with specific neuronal ion channels of the excitable membranes [183]. These 
peptides can be classified depending on their mode of action, such as effects on sodium (Na
+), calcium 
(Ca
2+), potassium (K
+) and chloride (Cl
-) ion channels [111,187]. Many of these peptides present a 
structural  motif designated as  an inhibitory cystine knot  (ICK), and therefore these molecules are 
named knottins. The ICK motif is composed of a triple-stranded, anti-parallel β-sheet, stabilized by a 
cystine knot containing three disulphide bridges [188,189], which confer rigidity to the molecules in 
addition to a stabilization of their secondary structures and relative resistance to denaturation [190].  
Although there are a great number of insecticidal peptides characterized in several spider species, 
little is known about insecticidal molecules in Loxosceles spiders. By studying L. intermedia venom, 
de Castro et al. [23] first described and characterized three isoforms of insecticidal peptides named 
LiTx1,  LiTx2  and  LiTx3  which  contain  ICK  motif  and  act  on  specific  ion  channels.  The 
chromatographic  fraction  containing  these  peptides  showed  potent  insecticidal  activity  against  the 
agricultural  pests  Spodoptera  species.  LiTx1  (7.4  kDa)  presents  some  sites  to  possible  
post-translational  modifications,  such  as  N-myristoylation,  protein  kinase  C  phosphorylation, 
amidation and casein kinase II phosphorylation. With regard to its specificity, the study was not able to 
determine  whether  LiTx1  interacts  with  Na
+  or  Ca
2+  channels.  LiTx2  (7.9  kDa)  and  may  present  
N-myristoylation, protein kinase C phosphorylation and amidation sites. Its specificity to ion channels 
was not determined. LiTx3 peptide (5.6 kDa) has also sites for N-myristoylation and protein kinase C 
phosphorylation.  Based  on  bioinformatic  analyses,  de  Castro,  et  al.  hypothesized  that  LiTx3  may 
interact with Na
+ channels. In 2006, a new isoform, LiTx4, was identified (GenBank nº  DQ388598.1).  
Transcriptome analysis of the L. intermedia venomous gland revealed ESTs with similarity to LiTx 
peptides described by de Castro et al. [23]. LiTx3 was the most abundant sequence in the L. intermedia 
transcriptome, comprising 32% of toxin-encoding messengers. LiTx2 had a representativeness of 11% 
in  relation  to  the  toxin-encoding  transcripts.  [27].  The  transcriptome  analysis  of  L.  intermedia 
venomous gland additionally revealed the presence of another class of ion channel-binding peptides. 
These peptides present similarity to neurotoxin Magi 3, a peptide isolated by Corzo et al. [26] from the 
venom of the Macrothele gigas spider. Magi 3 peptide is able to paralyze insects, although the authors 
did  not  confirm  whether  Magi  3  is  specific  for  insect  sodium  channels  or  also  acts  on  calcium  
channels [191].  
The specificity of insecticidal peptides for ion channels provides an important tool to understand 
their dynamic activity. Ion channels are transmembrane proteins involved in the control of ion fluxes 
across the membrane, regulating membrane potential and ion balance. Their activity is also related to 
the coordination of diverse cellular functions such as excitation-contraction coupling, hormone and 
neurotransmitter secretion and gene expression. Thus, the comprehension of the interaction between 
peptide-ionic channels allows a more refined investigation of the physiological role of ion channels, as 
well as the determination of possible therapeutic applications [192].  
The ability to discriminate insect ion channels confers to insecticidal peptides with considerable 
potential  in  the  development  of  an  efficient  bioinsecticide  for  the  control  of  economically 
disadvantageous  pests  or  insect  vectors  of  new  or  re-emerging  disease  [182,193].  Recombinant 
baculovirus containing the gene encoding an insecticidal peptide has been studied and tested against 
many  insect  pests,  such  as  Heliothis  virescens  (cotton  bollworm),  Laspeyresia  pomonella Toxins 2011, 3                                 
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(codlingmoth)  and  Neodiprion  sertifer  (European  sawfly)  [183,194].  This  biotechnological 
development could lead to alternative methods for chemical control, resulting in many benefits to the 
agricultural sector that will ultimately reduce economic losses. 
9. Serine Protease Inhibitors 
The control of proteases is normally achieved by the regulation of expression, secretion, activation 
of proenzymes and degradation. A second level of control is based on specific inhibition of activity. 
Despite  microorganisms  that  produce  non-proteinaceous  compounds  that  block  host  proteases,  the 
remaining all known natural protease inhibitors are proteins [195–197]. Among these natural protease 
inhibitors, the most extensively studied and described protein inhibitors of proteases are the group of 
serine protease inhibitors.  
Serine protease inhibitors can be classified into one of three different types,  according to their 
structures and the mechanism of inhibition: the canonical inhibitors, the non-canonical inhibitors and 
the serpins. The largest group is the canonical inhibitors, which are small proteins (14 to ~200 amino 
acid residues) represented mainly by the Kazal, BPTI (bovine pancreatic trypsin inhibitor), potato I 
and  STI  (soybean  trypsin  inhibitor)  families  [198,199].  Non-canonical  are  usually  found  in  
blood-sucking organisms and are responsible for blocking the blood-clotting cascade [196]. Serpins 
(serine protease inhibitors) are large proteins (typically 350 to 500 amino acids in size), also widely 
distributed in nature, and are abundant in human plasma. Similar to the canonical inhibitors, serpins 
exhibit  binding  loops  and  interact  with  the  target  enzyme  in  a  substrate-like  manner.  However, 
cleavage of the serpin loop by the protease leads to dramatic conformational changes in the global 
structure of the inhibitor [196,200,201].  
In brown spider venom, protease inhibitors were first reported in L. laeta [51]. The transcriptome 
analysis  approach,  which  detected  0.6%  of  sequences  with  identity  to  intracellular  coagulation 
inhibitor from Tachypleus tridentatus and sequences with identity to serine (or cysteine) proteinase 
inhibitors  from  Mus  musculus,  Aedes  aegypti,  Branchiostoma  lanceolatum,  Gallus  gallus,  and 
Boophilus microplus . Similar results were obtained for L. intermedia [27], in which one transcript 
presented significant similarity with a serine (or cysteine) peptidase inhibitor, clade I, member 1 from 
Mus musculus. In both cases (L. laeta and L. intermedia), the sequences analyzed were similar to 
serine proteinase inhibitors belonging to the Serpin superfamily.  
Playing  roles  as  potential  toxins,  serine  protease  inhibitors  have  been  intensively  described  in 
several snake venoms, especially for those of the Elapidae and Viperidae families [202]. In these 
venoms,  the  majority  of  inhibitors  characterized  belong  to  the  canonical  type,  particularly  the 
Kunitz/BPTI inhibitors of trypsin and chymotrypsin. The peptides were typically 6–7 kDa in size and 
were isolated from crude venoms and studied by different methods [203–210]. The identification of 
this  type  of  molecule  allowed  future  isolation  and  further  characterization  of  putative  protease 
inhibitors,  suggesting  the  possibility  of  a  biotechnological  application.  The  best  example  for  this 
purpose is Textilinin-1, which is a well-known 6.7 kDa Kunitz-type serine protease inhibitor from the 
venom of the snake Pseudonaja textilis which binds and blocks certain proteases, including plasmin 
and trypsin [211]. The ability to reversibly inhibit plasmin has raised the possibility of using this drug 
as an alternative to aprotinin (Trasylol
®), as a systemic antibleeding agent in cardiac surgery. Like Toxins 2011, 3                                 
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aprotinin,  Textilinin-1  (in  equimolar  concentrations)  almost  completely  inhibits  tissue 
plasminogenactivator-induced fibrinolysis of whole blood clots. In mouse bleeding models, Textilin-1 
shows shorter time of hemostasis compared to aprotinin and appears to be a more specific plasmin 
inhibitor than aprotinin [210–212]. 
Despite their presence in the majority of snake venoms, serine protease inhibitors have also been 
described and characterized in other organisms. Zhao et al. [213] isolated and characterized a 60 kDa 
serpin from skin secretions of Bufo andrewsi, which was denoted as Baserpin. This protein was able to 
irreversibly inhibit trypsin, chymotrypsin and elastase. Serine protease inhibitors are also present in 
spider  venoms,  particularly  in  the  venom  of  tarantulas  (Ornithoctonus  huwena  and  Ornithoctonus 
hainana).  The  prototypic  molecule  in  tarantula  venom  is  HWTX-XI,  6.1  kDa  peptide  from 
Ornithoctonus huwena venom, which belongs to the Kunitz-type family of serine protease inhibitors. 
Just like Kunitz-type toxins in snake venoms, HWTX-XI is considered to be a bi-functional toxin 
because it is a strong trypsin inhibitor as well as a weak Kv1.1 potassium channel blocker [214]. 
Zhao et al. [213] isolated and characterized a 60 kDa serpin from skin secretions of Bufo andrewsi, 
which was denoted as Baserpin. This protein was able to irreversibly inhibit trypsin, chymotrypsin and 
elastase. The considerations above represent just a few insights concerning serine protease inhibitors 
uses and applications. The great importance of proteases in numerous different biological processes 
and the large number of protease inhibitors described suggest their strong biotechnological potential. 
10. Conclusion 
Research in brown spider venom toxins has increased over recent years, but the challenges and 
opportunities are enormous. To move the field forward, scientists must have access to the biodiversity 
of spiders within their countries. Different Loxosceles genus spider species are reported to inhabit 
every continent [5,6,8], and bureaucracy related to the capture of spiders should not be a hindrance to 
researchers on toxinology area. Official collaborations with groups based where brown spiders are 
endemic will facilitate access to their venom.  
Another difficulty in working with Loxosceles venoms is the fact that the volume of venom is 
minute (just microliters, containing a few micrograms of protein, as previously discussed). This makes 
work difficult for researchers that use crude venom in their experiments. To overcome this difficulty, 
works can collect venom from hundreds, or even, thousands, of spiders during specific periods of the 
year  when  there  is  an  abundance  of  spiders  and  store  the  venom  under  appropriate  conditions  
(i.e., lyophilized or in solutions at −80 ° C) [18]. Alternatively, brown spiders could be captured from 
the wild and kept individually (because they kill one another) under laboratory conditions, using insect 
larvae  as  food  and  with  periodic  hydration  via  water-soaked  cotton  balls,  with  venom  collected  
as necessary.  
Another technical solution for venom production is the standardization of long-term primary culture 
of secretory cells from the venom gland and the production of venom in vitro. The culture of secretory 
cells from different venomous animals has shown promising results, and represents a good system with 
which to obtain toxins without capturing animals from the wild and without the related ecological 
disturbances.  To  date,  several  groups  have  reported  expertise  on  this  topic,  and  have  established 
protocols for the primary culture of secretory cells. Examples include those from the venom glands of Toxins 2011, 3                                 
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Crotalus durissus terrificus and Bothrops jararaca snakes [215,216], as well as those from the venom 
glands of the Phoneutria nigriventer spider [217]. Such protocols ensure that sufficient amounts of 
native toxins are produced and secreted for culture medium and used for technical purposes after 
purification. Unfortunately, for Loxosceles venom gland cells, there are no reports to date of successful 
primary  cultures  of  secretory  cells.  This  situation  represents  a  rational  challenge  for  the  future 
regarding the acquisition of sufficient amounts of native molecules. Finally, the venom of Loxosceles 
species is commercially available, as is the case for L. deserta (Sigma, St. Louis, USA).  
The cDNA library construction of L. intermedia venom gland [35], transcriptome analysis [27,51] 
and the cloning and synthesis of several recombinant toxins [29,32–37,39,43,52] is helping to elucidate 
the biology of Loxosceles genus and opening possibilities for biotechnology applications. Recombinant 
toxins have been expressed in bacteria, simple organisms that are easy to manipulate and cheap to 
work  with;  unfortunately  these  do  not  generate  co-  and  post-translational  modifications  such  as 
disulphide bonds and protein glycosylations. Certain recombinant molecules are expressed in their 
unfolded form, have incorrected conformations, are water insoluble, and have no biological function.  
With regard to phospholipase-D family members, these recombinant toxins purified from bacteria 
have biological functions compatible with those described for native toxins. For native toxins, it was 
already very well demonstrated that inflammatory response with cytokines release is induced at the 
bite site, and lipid content might be relevant for tissue damage [218,219]. These recombinant toxins 
induce  dermonecrosis,  platelet  aggregation,  increased  vessel  permeability,  deep  inflammatory 
responses, and phospholipase-D activity [34–37]. On the other hand, a great number of brown spider 
venom recombinant toxins synthesized by bacteria are water-insoluble and have no biological function. 
To surpass this technical obstacle, insoluble toxins can be refolded by methods of protein refolding 
[220],  but  the  final  concentration  of  refolded  toxins  obtained  is  generally  not  enough  for 
biotechnological uses.  
Alternatively,  toxins  can  be  synthesized  using  other  expression  models,  such  as  the  yeast  
Pichia pastoris [221], an organism that has subcellular organelles as endoplasmic reticulum and Golgi 
apparatus.  This  yeast  is  able  to  perform  co-  and  post-translational  modifications  of  proteins.  For 
Loxosceles toxins, preliminary experiments are underway [75], but a frequent problem to be overcome 
is  the  hyperglycosylation  of  secreted  proteins,  which  alters  the  biological  functions  of  the  toxins. 
Expression in systems of insect cells, such as Drosophila Schneider cells, is a possible alternative 
method  [222]  because  it  is  a  eukaryotic  expression  system,  in  which  proteins  undergo  
post-translational modifications.  
For Loxosceles toxins, again, experiments are just beginning and results are preliminary [75], but 
they can provide secreted toxins that are correctly folded and, in the near future, may be used as tools 
for biological evaluations. Baculovirus vector for protein expression in insect and mammalian system 
is also feasible [223], but we do not have information on Loxosceles molecules produced using this 
technique.  Finally,  the  mammalian  expression  system  is  a  rational  alternative  for  expression  of 
correctly folded recombinant proteins. Mammalian cells have the capacity for proper protein folding 
and assembly, as well as co- and post-translational modifications [224]. Currently, there are no data on 
Loxosceles venom toxins obtained using this system. However, because this model is a viable method 
for recombinant proteins of therapeutic use, scientists are expected to explore this system in the future.  Toxins 2011, 3                                 
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The advancement of Loxosceles venom toxin research will also involve techniques from proteomic 
analysis. These techniques generally have high sensitivity and accuracy and normally use low venom 
concentration for analysis. To date, at least two works have been completed addressing this topic. By 
using  proteomics  methodologies,  such  as  bi-dimensional  electrophoresis,  N-terminal  amino  acid 
sequencing  and  mass  spectrometry,  eleven  isoforms  for  phospholipase-D  toxin  were  identified  in  
L. gaucho venom [25]. In addition, through mass spectrometry analysis using L. intermedia crude 
venom, 39 proteins were identified, and putative effects for envenomation were discussed [24]. The 
use  of  combinatorial  data  from  proteomic  and  molecular  biology  techniques,  such  as  mass 
spectrometry, transcriptome analysis and cDNA library constructions, will open possibilities for the 
discovery of novel toxins in complex venoms [225].  
Additionally,  in  the  near  future,  the  biotechnological  use  of  Loxosceles  toxins  could  provide 
information related to the tridimensional structure of identified toxins, through crystallography and  
X-ray diffraction and/or nuclear magnetic resonance for soluble toxins [59]. Findings in these areas 
will  bring  insight  related  to  the  molecular  structure  of  toxins  and  will  be  very  important  for  the 
discovery of catalytic sites, sites that interact with natural substrates or ligands, and from such data, 
synthetic ligands, analogs, or inhibitors could be designed for biotechnological purposes.  
Regarding  Loxosceles  spider  venom  toxins,  a  recombinant  phospholipase-D  from  L.  laeta  was 
analyzed by crystallography and X-ray diffraction. The data collected allowed description of the amino 
acid residues involved in catalysis and metal ion coordination important for sphingomyelinase activity 
[226]. Experiments using other isoforms of phospholipase-D from L. intermedia venom (LiRecDT1, 
LiRecDT2, LiRecDT6, GFP-LiRecDT1, and LiRecDT1H12A, with a mutation on the catalytic site, 
[46]) are currently being conducted using crystallography and X-ray diffraction. Additionally, other 
Loxosceles  recombinant toxins  (enzymes  and peptides)  could  be  evaluated and represent potential 
biological tools in a wide range of fields. 
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